Business Context and Reporting Period
This Form 8-K, dated May 11, 2020, reports on India Globalization Capital, Inc. (IGC). The filing details the execution of a definitive Share Purchase Agreement to acquire the remaining outstanding shares of Evolve I, Inc., a hemp product development company incorporated in Washington State.
Key Financial Metrics and Transaction Details
Acquisition Consideration:
- Closing Payment: Approximately $229,590 in cash and 22,040 shares of IGC common stock.
- Operational Milestones: Approximately $200,000 in cash and 300,000 shares of IGC common stock payable upon achieving specific operational goals.
- Earn-out Structure (Revenue/Profit Targets):
- Year 1: Approximately $0.9 million.
- Year 2: Approximately $1.6 million.
- Year 3: Approximately $2.5 million.
- Total Potential Consideration: Approximately $6 million (cash and stock combined), consistent with the initial non-binding term sheet.
Target Company (Evolve) Financials (FY Ended Dec 31, 2019):
- Revenue: Approximately $126,000 (un-audited).
- Net Loss: Approximately $24,000.
- Total Assets: Approximately $29,000.
- Net Worth: Negative approximately $25,000.
IGC Financials: The filing text does not provide specific revenue, profit, cash flow, or debt metrics for IGC for the current period.
Material Changes and Transaction History
IGC previously acquired a 20% stake in Evolve on March 13, 2020, for $148,722.75 in cash and 100,514 shares of IGC stock. The current filing represents the agreement to acquire the remaining 80% of the company. The investment in Evolve exceeds 10% of IGC's total assets, triggering specific disclosure requirements under Regulation S-X.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The transaction is subject to customary closing conditions. IGC expects to file audited financial statements and pro forma financial information for Evolve within 71 days of closing.
Risks and Contingencies:
- Transaction Risks: Failure to meet operational goals or revenue/profit targets required for earn-out payments.
- External Factors: Impact of the COVID-19 outbreak, travel restrictions, and disruption of the Hong Kong economy.
- Regulatory Environment: Changes in federal, state, or local laws, specifically regarding the FDA's position on hemp-based products.
- Commercialization: Risks associated with the failure to commercialize products or technologies.
Investor Verification Checklist
- Verify the closing date and final consideration paid for the remaining 80% of Evolve shares.
- Review the upcoming audited financial statements of Evolve (due within 71 days of closing) to confirm asset and liability valuations.
- Monitor the achievement of the specific operational goals and revenue/profit targets required to trigger the $5 million earn-out.
- Assess the impact of FDA regulations on hemp products on Evolve's future revenue potential.
- Confirm the dilution impact of the total 422,514 shares of IGC stock issued or issuable for the transaction.